XML 90 R81.htm IDEA: XBRL DOCUMENT v3.23.1

JOINT VENTURES AND ASSOCIATES (Details) - USD ($)		3 Months Ended		9 Months Ended
	Dec. 28, 2022	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
JOINT VENTURES
Assets in joint ventures and associates		$ 39,185,745		$ 39,185,745		$ 38,554,092
Liabilities in joint ventures and associates		221,014		221,014		717,948
Share of profit or loss of joint ventures and associates		378,145	$ (203,954)	1,260,433	$ 715,133
Trigall Genetics S.A.
JOINT VENTURES
Liabilities in joint ventures and associates		221,014		221,014		717,948
Share of profit or loss of joint ventures and associates				496,934	828,307
Synertech Industrias S.A.
JOINT VENTURES
Assets in joint ventures and associates		35,892,032		35,892,032		35,646,740
Share of profit or loss of joint ventures and associates				337,543	(48,882)
Indrasa Biotecnologia S.A.
JOINT VENTURES
Assets in joint ventures and associates						70,466
Share of profit or loss of joint ventures and associates				(57,033)	50,417
Alfalfa Technologies S.R.L
JOINT VENTURES
Assets in joint ventures and associates		44,840		44,840		74,827
Moolec Science Limited
JOINT VENTURES
Assets in joint ventures and associates						2,759,059
Share of profit or loss of joint ventures and associates					$ (114,709)
Moolec Science S.A.
JOINT VENTURES
Assets in joint ventures and associates		$ 3,248,873		3,248,873		$ 3,000
Share of profit or loss of joint ventures and associates				$ 482,989
Moolec Science S.A. | Ordinary shares
JOINT VENTURES
Number of shares received in exchange for all of its ownership in Moolec Sciente Limited ordinary shares	1,560,000
Ownership held (in shares)		1,860,000		1,860,000

X

- Definition

The number of shares received from joint ventures in exchange for consideration contributed.

+ References

No definition available.

+ Details

Name:	biox_InvestmentInJointVenturesNumberOfSharesReceived
Namespace Prefix:	biox_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of investments accounted for using the equity method, asset position.

+ References

No definition available.

+ Details

Name:	biox_InvestmentsAccountedForUsingEquityMethodAssets
Namespace Prefix:	biox_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of investments accounted for using the equity method, liability position.

+ References

No definition available.

+ Details

Name:	biox_InvestmentsAccountedForUsingEquityMethodLiability
Namespace Prefix:	biox_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The number of shares of the joint ventures held by the entity at reporting date.

+ References

No definition available.

+ Details

Name:	biox_JointVentureNumberOfSharesHeld
Namespace Prefix:	biox_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfJointVenturesLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 28
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 23
-Subparagraph g
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_g&doctype=Standard
-URIDate 2022-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2022-03-24
-Paragraph 39M
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M_b&doctype=Standard
-URIDate 2022-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 82
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_c&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	ifrs-full_JointVenturesAxis=biox_TrigallGeneticsS.a.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_JointVenturesAxis=biox_SynertechIndustriasS.aMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_JointVenturesAxis=biox_IndrasaBiotecnologaS.a.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_JointVenturesAxis=biox_AlfalfaTechnologiesS.r.lMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_JointVenturesAxis=biox_MoolecScienceLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_JointVenturesAxis=biox_MoolecScienceS.a.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: